Search for 'Provider:BMC cancer'

Evaluation of the efficacy and safety of lanreotide in combination with targeted therapies in patients with neuroendocrine tumours in clinical practice: a retrospective cross-sectional analysis.

By Castellano, Daniel. BMC cancer, 2015 . 15:495. , Formato Vancouver: Capdevila J, Sevilla I, Alonso V, Antón Aparicio L, Jiménez Fonseca P, Grande E et al. Evaluation of the efficacy and safety of lanreotide in combination with targeted therapies in patients with neuroendocrine tumours in clinical practice: a retrospective cross-sectional analysis. BMC Cancer. 2015 Jul 4;15:495.

Place Hold on Evaluation of the efficacy and safety of lanreotide in combination with targeted therapies in patients with neuroendocrine tumours in clinical practice: a retrospective cross-sectional analysis.

Capecitabine and irinotecan with bevacizumab 2-weekly for metastatic colorectal cancer: the phase II AVAXIRI study.

By Grávalos Castro, Cristina. BMC cancer, 2015 . 15:327. , Formato Vancouver: García Alfonso P, Chaves M, Muñoz A, Salud A, García González M, Grávalos C et al; Spanish Cooperative Group for the Treatment of Digestive Tumors (TTD). Capecitabine and irinotecan with bevacizumab 2-weekly for metastatic colorectal cancer: the phase II AVAXIRI study. BMC Cancer. 2015 Apr 29;15:327.

Place Hold on Capecitabine and irinotecan with bevacizumab 2-weekly for metastatic colorectal cancer: the phase II AVAXIRI study.

A randomized phase II study of capecitabine-based chemoradiation with or without bevacizumab in resectable locally advanced rectal cancer: clinical and biological features.

By Grávalos Castro, Cristina. BMC cancer, 2015 . 15:60. , Formato Vancouver: Salazar R, Capdevila J, Laquente B, Manzano JL, Pericay C, Villacampa MM et al. A randomized phase II study of capecitabine-based chemoradiation with or without bevacizumab in resectable locally advanced rectal cancer: clinical and biological features. BMC Cancer. 2015 Feb 26;15:60.

Place Hold on A randomized phase II study of capecitabine-based chemoradiation with or without bevacizumab in resectable locally advanced rectal cancer: clinical and biological features.

Safety and effectiveness of vinflunine in patients with metastatic transitional cell carcinoma of the urothelial tract after failure of one platinum-based systemic therapy in clinical practice

By Castellano, Daniel. BMC cancer, 2014 . 14:779. , Formato Vancouver: Castellano D, Puente J, de Velasco G, Chirivella I, López Criado P, Mohedano N et al. Safety and effectiveness of vinflunine in patients with metastatic transitional cell carcinoma of the urothelial tract after failure of one platinum-based systemic therapy in clinical practice. BMC Cancer. 2014 Oct 24;14:779.

Place Hold on Safety and effectiveness of vinflunine in patients with metastatic transitional cell carcinoma of the urothelial tract after failure of one platinum-based systemic therapy in clinical practice

Antiproliferative effects of lanreotide autogel in patients with progressive, well-differentiated neuroendocrine tumours: a Spanish, multicentre, open-label, single arm phase II study.

By Castellano, Daniel. BMC cancer 2013 . 13:427. , Formato Vancouver: Martín-Richard M, Massutí B, Pineda E, Alonso V, Marmol M, Castellano D. TTD (Tumores del Tracto Digestivo) Study Group. Antiproliferative effects of lanreotide autogel in patients with progressive, well-differentiated neuroendocrine tumours: a Spanish, multicentre, open-label, single arm phase II study. BMC Cancer. 2013 Sep 20;13:427.

Place Hold on Antiproliferative effects of lanreotide autogel in patients with progressive, well-differentiated neuroendocrine tumours: a Spanish, multicentre, open-label, single arm phase II study.

Case-control study for colorectal cancer genetic susceptibility in EPICOLON: previously identified variants and mucins

By Morillas Sainz, Juan Diego. BMC Cancer, 2011 . 11:339. , Formato Vancouver: Abulí A, Fernández-Rozadilla C, Alonso-Espinaco V, Muñoz J, Gonzalo V, Bessa X, et al. Case-control study for colorectal cancer genetic susceptibility in EPICOLON: previously identified variants and mucins. BMC Cancer. 2011;11:339.

Place Hold on Case-control study for colorectal cancer genetic susceptibility in EPICOLON: previously identified variants and mucins